Search

Displaying results 1931 - 1940 of 10000 in total
  1. Drug

    Ferric cation

    go.drugbank.com/drugs/DB13949
    ApprovedWithdrawn

    Iron deficiency may be characterized without the development of anemia, and may result in functional impairments affecting cognitive development and immunity mechanisms, as well as infant or maternal mortality … Iron is an essential element involved in various metabolic processes, including oxygen transport, deoxyribonucleic acid (DNA) synthesis, and energy production in electron transport [A32514].

  2. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

  3. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. … The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function.

  4. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Hexylcaine hydrochloride is also known as cyclaine and osmocaine. It is a short acting local anesthetic that acts through inhibition of sodium channels.

  5. Drug

    Brompheniramine

    go.drugbank.com/drugs/DB00835
    Approved

    Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

    Mixtures: M-end Wc, M-end PESynonyms: 3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine, 3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine
  6. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    Uridine triacetate, formerly known as vistonuridine, is an orally active prodrug of the naturally occurring nucleoside uridine. … It is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself.

  7. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor.

  8. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  9. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    [A246609] Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications. … at position 1 (N-terminal end).

  10. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized … [L41315] Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.[L49901]

    Synonyms: N-Methionylleptin